The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.
It's February 2016 and we have so much EM:RAP this month, we added an extra day!
Honestly I did not like the organization of the material and that can be a bias in the learning process
Lilian J GomesMedical GraduateFormer Biological Sciences Graduate StudentCertified in PedagogyFormer Research/Tx Fellow
Totally agree with high dose NTG and BiPAP for acute pulmonary edema, but we have been dosing it a bit differently for years and it works well. We start high--200-300mcg/minute and then rapidly titrate down. We typically instruct the nurse to cut the dose in half when the BP responds, checking BPs q 5 minutes. Theoretically decreases time to effective dose and is well tolerated.
Regardin Nexus ct chest rules. I suppose it is undersood that aloc makes the rule useless? For some reason that is left out. Am i missing someting?
I'm part of a group of physicians for my health care system that is looking to develop an Advanced Diagnostic Pathway for Atrial Fibrillation including cardioversion. After reviewing the EMRAP episode from February 2016, I noted that Cam Berg's pathway mentions the patient's CHADS2VASC score when considering anticoagulation; however, the pathway does not take this into account when considering patients for cardioversion in the setting of Afib with RVR. Is this something that should also be taken into account when deciding the population to consider for cardioversion?
What you do matters.